News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Ruben Ruiz Vega: Sunshine, science, and amazing company at FLASCO
Ruben Ruiz Vega/X
Mar 23, 2025, 16:24

Ruben Ruiz Vega: Sunshine, science, and amazing company at FLASCO

Ruben Ruiz Vega, Hematology and Oncology Fellow at the University of Florida, shared a post on X:

“Sunshine, science, and amazing company!

Had a fantastic time at the Florida Society of Clinical Oncology Fellows and Residents (FLASCO)! Grateful for the opportunities to grow, network, and (of course) enjoy the Florida vibes!”

cancer FLASCO Florida Society of Clinical Oncology Fellows and Residents OncoDaily Oncology Ruben Ruiz Vega
Special Coverage
Oncolibrary
Jun 1, 2025, 13:48
Romiplostim for Chemotherapy-induced Thrombocytopenia Results from global phase iii trial in Gi cancers
Opinion
Jun 1, 2025, 13:42
Efficacy of IL-6R Blockade with Sarilumab in a Quadruple Immuno-Oncology Regimen for Patients with Unresectable Stage III/IV Melanoma
Oncolibrary
Jun 1, 2025, 13:02
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus Ipilimumab Continues to Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Oncolibrary
Jun 1, 2025, 12:40
Metacure Cohorts B2 Results: Intensified Hormonal Blockade and SBRT for PSMA-PET Detected Oligometastatic Prostate Adenocarcinoma
Oncolibrary
Jun 1, 2025, 12:03
EV-302 Updates at ASCO 2025: Enfortumab Vedotin Plus Pembrolizumab Doubles Complete Response Rate in Advanced Urothelial Carcinoma
Oncolibrary
Jun 1, 2025, 11:55
Tagitanlimab Boosts Chemotherapy in Nasopharyngeal Cancer: Phase 3 Results at ASCO 2025
Oncolibrary
Jun 1, 2025, 11:51
FIRE-4 Study Results: Cetuximab Re-challenge in Metastatic RAS Wild-Type Colorectal Cancer
Oncolibrary
Jun 1, 2025, 11:45
Combining Darolutamide and Goserelin: A New Frontier in Fighting Salivary Gland Cancer at ASCO 2025
Oncolibrary
Jun 1, 2025, 11:44
SURE-02 Phase 2 Trial Interim Results: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Bladder Preservation in Muscle-Invasive Bladder Cancer
Blog
Jun 1, 2025, 11:42
Estela Rodriguez: Day 2 ASCO25 Agenda
Blog
Jun 1, 2025, 11:35
Mario Balsa: Breaking from ASCO 2025 - DESTINY-Gastric04 Trial
Blog
Jun 1, 2025, 11:33
Cristiane Bergerot: Genomic Insights from IMmotion010